VKORC1 rs992446: Warfarin Sensitivity and Dosing

What each genotype means

What is rs992446 and Where Does It Sit?

The single nucleotide polymorphism rs992446 is a non-coding variant situated within the 5-prime upstream promoter region of the VKORC1 gene on chromosome 16 (often designated c.-1639G>A). Because it resides in the promoter region rather than in a protein-coding exon, it does not alter the amino acid sequence of the resulting enzyme. Instead, the substitution of adenine (A) for guanine (G) disrupts an essential transcription factor binding motif. This disruption significantly dampens the rate at which the gene is transcribed into messenger RNA, reducing baseline cellular levels of the vitamin K epoxide reductase complex subunit 1 enzyme. In pharmacogenomics literature and clinical panels, rs992446 is frequently cited interchangeably with or tagged by rs9934438 (1173C>T), as these variants are in nearly complete linkage disequilibrium in most major populations. As a core component of clinical testing panels, rs992446 is recognized as an Association for Molecular Pathology (AMP) Tier 1 pharmacogenetic marker.

The Biological Function of the VKORC1 Enzyme

The VKORC1 gene encodes the catalytic subunit of vitamin K epoxide reductase, an essential enzyme anchored within the endoplasmic reticulum membrane. This enzyme plays an indispensable role in the cyclic recycling of vitamin K, catalyzing the conversion of inactive vitamin K 2,3-epoxide back into active reduced vitamin K hydroquinone. Reduced vitamin K functions as an obligatory cofactor for gamma-glutamyl carboxylase, the enzyme responsible for activating coagulation factors II (prothrombin), VII, IX, and X, along with natural anticoagulant proteins C and S. Warfarin and related oral coumarin anticoagulants achieve their therapeutic effect by selectively inhibiting VKORC1, thereby depleting active vitamin K pools and lowering the production of functional clotting factors. Because individuals with the -1639A allele express lower baseline amounts of the VKORC1 target enzyme, fewer drug molecules are required to achieve effective enzyme inhibition, resulting in heightened drug sensitivity.

Clinical Evidence and Association with Warfarin Dosing

The link between rs992446 and warfarin dosing represents one of the strongest and most extensively validated gene-drug interactions in modern pharmacogenomics. Decades of large-scale clinical trials and genome-wide association studies confirm that the A allele correlates with substantially lower required maintenance doses to achieve the target International Normalized Ratio (INR). In therapeutic guidelines published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG), recommendations incorporating VKORC1 genotype alongside CYP2C9 variants receive the highest level of evidentiary support. Multiple randomized controlled trials have demonstrated that pharmacogenetic dosing algorithms incorporating rs992446 reduce the time required to achieve stable therapeutic anticoagulation and lower the incidence of early adverse bleeding events. Notably, VKORC1 status dictates sensitivity to the drug target, whereas CYP2C9 polymorphisms dictate how rapidly the active S-warfarin enantiomer is cleared by hepatic metabolism.

Population Frequencies Across Diverse Ancestries

The distribution of the rs992446 variant exhibits dramatic variation across global geographic and ancestral populations, explaining why baseline anticoagulation requirements differ substantially between demographic groups. The variant A allele is the predominant major allele in East Asian populations, frequently exceeding an allele frequency of 85% to 90%, which accounts for the systematically lower average warfarin maintenance doses traditionally needed by patients of East Asian heritage. In populations of European descent, the allele frequency typically ranges between 35% and 45%, resulting in a broad mixture of sensitive and intermediate dosing phenotypes. In contrast, the A allele is considerably less common in indigenous African and African American populations, where allele frequencies generally range from 10% to 15%. Because African ancestry cohorts display greater genetic diversity at the VKORC1 and CYP2C loci, predictive dosing algorithms must evaluate additional variants, such as rs12777823, to ensure equity and precision.

What You Can and Cannot Do with This Result

Discovering your rs992446 genotype offers valuable context regarding your biological sensitivity to coumarin-based anticoagulants, but it cannot be used in isolation to make autonomous health decisions. First and foremost, patients must never self-adjust, discontinue, or initiate warfarin dosing based on a genetic report. Warfarin has an exceptionally narrow therapeutic window, where deviations can precipitate catastrophic thrombosis or severe, life-threatening hemorrhages. In clinical practice, genotype represents only one piece of the puzzle: an individual's required dose is simultaneously governed by age, body surface area, concurrent medications, dietary intake of vitamin K, and hepatic renal function. If you are prescribed or currently taking warfarin, share your genetic findings directly with your prescribing physician or clinical pharmacist. Clinicians can input your genotype into peer-reviewed CPIC pharmacogenetic dosing algorithms to calculate safer initial dosing strategies or determine whether direct oral anticoagulants (DOACs) are preferable.

Frequently asked questions

Sources & further reading

Related variants in VKORC1